Darboren 40 Injection

• Chronic Kidney Disease (CKD) in patients on dialysis and patients not on dialysis
• The effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy

Dosage & Administration:
Recommended starting dose for patients with CKD on dialysis
• 0.45 mcg/kg intravenously or subcutaneously weekly or
• 0.75 mcg/kg intravenously or subcutaneously every 2 weeks
• Intravenous route is recommended for patients on hemodialysis
Recommended starting dose for patients with CKD not on dialysis
• 0.45 mcg/kg intravenously or subcutaneously at 1 month interval
Recommended starting dose for pediatric patients with CKD
• 0.45 mcg/kg intravenously or subcutaneously weekly
• Patients with CKD not on dialysis may also be initiated at 0.75 mcg/kg every 2 weeks
Recommended starting dose for patients with cancer on chemotherapy
• 2.25 mcg/kg subcutaneously weekly, or
• 500 mcg subcutaneously every 3 weeks